{"nct_id":"NCT02314143","title":"Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib","status":"TERMINATED","status_verified_date":"2018-09","start_date":"2013-11-13","start_date_type":"ACTUAL","primary_completion_date":"2017-01-19","primary_completion_date_type":"ACTUAL","completion_date":"2017-01-19","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["GSK"]}